Norcliffe Capital

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, established in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm specializes in developing advanced diagnostics for the early detection of various cancers, focusing on Stage I and Stage II malignancies where timely intervention can significantly improve patient outcomes. Utilizing a combination of infrared spectroscopy and artificial intelligence, Dxcover's technology enables the detection of cancer from a simple blood sample, allowing for same-day diagnosis and patient stratification. This innovative approach aims to enhance treatment options and ultimately improve survival rates and quality of life for patients.

Oxford Endovascular develops a neurovascular device to treat brain aneurysms. The device uses origami-inspired engineering with a laser-cut metal alloy that has shape-memory, enabling a catheter-delivered implant to expand into a tiny mesh tube that conforms to the vessel. By diverting blood flow away from the aneurysm, it promotes healing and reduces the risk of rupture.

Glen Clova Scientific is focused on developing a new generation of active biological drugs that aim to form natural antibodies against harmful targets. The company's innovative approach enhances the quality of treatment for chronic diseases by minimizing the need for safety monitoring and reducing the frequency of dosing. This not only helps to lower the overall cost of treatment for patients but also expands access to healthcare in markets with limited infrastructure. Through its advancements in biologic drug development, Glen Clova Scientific seeks to improve patient outcomes and provide effective therapeutic options.

SMi Systems is a biomedical research and medical equipment manufacturing organization that specializes in developing advanced discovery and diagnostic tools. Its flagship product, SMi Drug Discovery, is a high-performance diagnostic device capable of detecting diseases within the first 24 hours of infection. This innovative device can simultaneously identify multiple diseases and process numerous patient samples in a matter of minutes. By facilitating the detection of individual disease-associated molecules, SMi Systems' automated and high-throughput diagnostic tools enable scientists to measure critical molecular interactions essential for understanding therapeutic mechanisms. This capability allows researchers to observe a vast diversity of molecular interactions across various disease areas and monitor drug binding to their targets, thereby advancing scientific research and clinical diagnostics.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, established in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm specializes in developing advanced diagnostics for the early detection of various cancers, focusing on Stage I and Stage II malignancies where timely intervention can significantly improve patient outcomes. Utilizing a combination of infrared spectroscopy and artificial intelligence, Dxcover's technology enables the detection of cancer from a simple blood sample, allowing for same-day diagnosis and patient stratification. This innovative approach aims to enhance treatment options and ultimately improve survival rates and quality of life for patients.

Aureum Diagnostics is a point of care diagnostics platform and medical equipment manufacturer focused on developing innovative diagnosis and testing tools for critical health conditions, including COVID-19. The company has created an electrochemical sensor and a handheld, low-cost instrument that integrates proprietary sensors, reagents, and instrumentation innovations. This technology allows clinicians to obtain rapid and highly sensitive measurements of multiple biologically significant targets, enhancing the efficiency and accuracy of medical diagnostics.

Biosceptre International Limited is a biopharmaceutical company based in Babraham, United Kingdom, focused on researching and developing innovative antibody products targeting the nf-P2X7 receptor for cancer treatment. Established in 2013, the company creates polyclonal antibodies aimed at treating various forms of skin cancer, including basal cell carcinoma and advanced basal cell carcinoma, as well as developing systemic antibodies for a range of tumors. Additionally, Biosceptre is advancing a therapeutic anti-cancer vaccine and is involved in the development of chimeric antigen receptor T-cell therapy. By employing multiple modalities, including systemic antibodies and vaccines, the company aims to provide effective therapeutic options for cancer patients globally.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, established in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm specializes in developing advanced diagnostics for the early detection of various cancers, focusing on Stage I and Stage II malignancies where timely intervention can significantly improve patient outcomes. Utilizing a combination of infrared spectroscopy and artificial intelligence, Dxcover's technology enables the detection of cancer from a simple blood sample, allowing for same-day diagnosis and patient stratification. This innovative approach aims to enhance treatment options and ultimately improve survival rates and quality of life for patients.